NEW YORK, Oct. 24 - Xenon Genetics, a privately held Canadian genomics firm, has acquired the lipid metabolism drug-discovery program of QuantaNova Canada, Xenon said on Wednesday. 

The acquisition, which includes a portfolio of novel genes and proprietary screening and diagnostic assays, is intended to help Xenon develop therapeutics for diabetes, obesity, and cardiovascular disease, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.